Lemborexant
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Initiation and Maintenance Disorders
Conditions
Sleep Initiation and Maintenance Disorders
Trial Timeline
Nov 30, 2022 → May 24, 2024
NCT ID
NCT05594589About Lemborexant
Lemborexant is a phase 2 stage product being developed by Eisai for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT05594589. Target conditions include Sleep Initiation and Maintenance Disorders.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05594589 | Phase 2 | Completed |
| NCT04890561 | Phase 1 | Completed |
| NCT04555733 | Phase 1 | Completed |
| NCT04573556 | Pre-clinical | Completed |
| NCT03443063 | Phase 1 | Completed |
| NCT03440424 | Phase 1 | Completed |
Competing Products
20 competing products in Sleep Initiation and Maintenance Disorders